Imatinib mesylate (Gleevec) is a type II inhibitor that inhibits ABL, PDGFR, and c-Kit, and was originally designed to target BCR-ABL, a driver mutation in chronic myeloid leukemia (CML; Fig. 3). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.